Special Issue "HDAC Inhibitors"

Guest Editor
Prof. Dr. H. Miles Prince
Centre for Blood Cell Therapies, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett St Melbourne 8006, Victoria, Australia
E-Mail:
Interests: blood clotting; bleeding disorders; transfusion medics; myeloma therapy (clinical and pre-clinial)and biology; cutaneous T cell lymphoma (clinical); immunotherapy; epigenetics

Dear Colleagues,

Histone deacetylase inhibitors are clearly effective therapeutic tools in the treatment of cancers, particularly haematological malignancies. The purpose of this special issue is to provide the reader with a focused review of on the current place of HDACi as a therapy, particularly in blood cancers. We hope to provide a broad overview of the rationale behind their use, with specific papers focusing on diseases where they clearly have biological effects - NHL, Hodgkin disease, myeloid malignancies. Finally we hope to have two seperate papers examining mechanisms of resistance and common toxicities.

I hope you will be able to contribute to what I see will be a valuable compendium of insightful reviews in this very topical subject.

Prof. Dr. H. Miles Prince
Guest Editors

Submission

All manuscripts should be submitted to pharmaceuticals@mdpi.org with a copy to the Guest Editor. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.

• histone deacetylase
• epigenetics
• demethylation
• novel therapies
• transcription factors

Manuscript ID: Pharmaceuticals-20091114-hdac-Ellis-us
Title: Histone Deacetylase Inhibitors; Advancing Therapeutic Strategies in Hematological and Solid Malignancies
Author: Leigh Ellis
Affiliation: Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA
Abstract: Advancement in the understanding of cancer development over recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with standard treatments or with other experimental chemotherapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using HDACI.